We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
-$51.8M
Cap. Flow %
-3.83%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Consumer Discretionary 0.08%
3 Financials 0.04%
4 Consumer Staples 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$148M 10.94%
15,239,444
+800,000
+6% +$7.21M
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$141M 10.45%
2,496,167
-446,800
-15% -$22.7M
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.64B
$86.5M 6.4%
2,240,928
-544,000
-20% -$17.6M
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
$68.4M 5.06%
1,819,215
+172,900
+11% +$5.56M
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$50.7M 3.75%
968,659
-13,100
-1% -$626K
TVTX icon
6
Travere Therapeutics
TVTX
$5.17B
$49.8M 3.68%
2,579,380
-67,700
-3% -$1.35M
AGN
7
DELISTED
Allergan plc
AGN
$45.3M 3.35%
+145,000
New +$43.2M
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
$38.4M 2.84%
1,186,630
+264,830
+29% +$11.5M
NVRO
9
DELISTED
NEVRO CORP.
NVRO
$32.7M 2.42%
484,279
-122,532
-20% -$6.56M
TEVA icon
10
Teva Pharmaceuticals
TEVA
$40.4B
$31.6M 2.34%
481,000
+321,000
+201% +$19.8M
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
$28.5M 2.11%
383,242
-3,084
-0.8% -$207K
GWPH
12
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$27.8M 2.06%
400,000
+100,000
+33% +$8.15M
XNCR icon
13
Xencor
XNCR
$1.45B
$27.1M 2.01%
1,854,784
+100,000
+6% +$1.34M
RXDX
14
DELISTED
Ignyta, Inc.
RXDX
$24.3M 1.8%
1,812,060
-119,540
-6% -$1.44M
IOVA icon
15
Iovance Biotherapeutics
IOVA
$2.04B
$23.2M 1.71%
3,000,161
+44,705
+2% +$310K
TLPH icon
16
Talphera
TLPH
$68M
$23.1M 1.71%
299,788
-13,415
-4% -$1.15M
SRPT icon
17
CALL
Sarepta Therapeutics
SRPT
$1.64B
$19.3M 1.43%
500,000
+200,000
+67% +$6.48M
BAX icon
18
Baxter International
BAX
$12.8B
$18.5M 1.37%
485,000
+425,000
+708% +$15.5M
FPRX
19
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18M 1.33%
434,129
+150,000
+53% +$5.03M
AGTC
20
DELISTED
Applied Genetic Technologies Corporation
AGTC
$17.6M 1.3%
861,513
+10,521
+1% +$162K
LJPC
21
DELISTED
La Jolla Pharmaceutical Company
LJPC
$17.5M 1.3%
649,515
-5,000
-0.8% -$136K
DERM
22
DELISTED
Dermira, Inc.
DERM
$17.4M 1.29%
502,000
+30,000
+6% +$861K
QURE icon
23
uniQure
QURE
$2.75B
$16M 1.18%
967,093
+276,824
+40% +$5.13M
QTNT
24
DELISTED
Quotient Limited Ordinary Shares
QTNT
$14.3M 1.06%
22,339
+2,919
+15% +$1.61M
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$123B
$13.8M 1.02%
+110,000
New +$13.3M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $51.8M in Q4 2015, closing 45 positions and reducing 31 holdings. Its most notable exit was RELYPSA INC COM, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Perceptive Advisors opened a new position in Allergan plc worth $45.3M.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.